Since the possibility of a clinical phenotype has been reported also for carriers of variants in the SLC22A2 and SLC2A9 genes [2, 3], unraveling the relationship between genotype and clinical manifestations would be relevant for understanding the pathophysiology of kidney damage in patients with hypouricemia. The gene discussed is SLC22A2; the disease is Nephropathy.